OS Therapies, a Phase IIb biotechnology company recently made headlines in Yahoo Finance. The announcement focused on the acquisition of BlinkBio’s Next Generation ADC Technology Platform.
OS Therapies is based in the Eastern Shore Innovation Center in Cambridge, Maryland. Their focus is on the identification, development and commercialization of treatments for Osteosarcoma (OS).
President and CEO, Paul Romness said, “OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults.”
Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. Romness added, “we are trying to answer the calls for new treatments, considering there have been no new treatments for Osteosarcoma in over 30 years.”